![Venetron®: New Research Shows Benefits to Women’s Health](https://cdn.shopify.com/s/files/1/0094/1090/4143/files/9_e9ca69a2-1aae-4ce3-9a79-a3c2e046b65d.png?v=1706819248)
Derived from a patented, purified and powdered extract of Apocynum venetum L., Venetron® is a unique standardized rafuma leaf extract containing no less than 2% hyperoside and no less than 2% isoquercitrin that provides unique benefits for women’s health.
In fact, Venetron® has been shown in several placebo-controlled human clinical trials to support a positive outlook, alleviate stress, improve sleep quality, and reduce premenstrual and menstrual complaints.*
In addition, a randomized, double-blind, placebo-controlled, parallel-group comparison study was just published in the journal Japanese Pharmacology & Therapeutics that looked at 42 healthy Japanese women randomly assigned to receive either Venetron® (50 mg) or a placebo daily for one menstrual cycle.
![MDQ Results](https://cdn.shopify.com/s/files/1/0094/1090/4143/files/venetron_img2.png?v=1706815247)
Women who received Venetron® reported significant improvements in symptoms described in a Menstrual Distress Questionnaire. Areas of reported improvement included autonomic reactions, concentration and behavioral changes before menstruation, as well as pain, concentration and control during menstruation.*
In addition, women who received Venetron® showed significant improvement in the initiation and maintenance of sleep.*
The following differentiators support formulation with Venetron® over other women’s health ingredients:
- Abundant evidence: Seven clinical trials, including one on safety
- Cost-effective low dosage of 50 mg per day
- Delivery format versatility
- Transparent sourcing
- Transparent sourcing and sustainable practices ensuring long-term reliability
![Venetron®](https://cdn.shopify.com/s/files/1/0094/1090/4143/files/10_dfac0ea3-dbd6-472b-a3b8-e19282a8bde1.png?v=1706819248)
In a survey conducted by a Japanese think tank, Venetron® ranked first in perceptual experience, surpassing other mood support ingredients. In that survey, approximately 80% of consumers reported superior satisfaction, demonstrating a 3.5 times higher satisfaction rate compared to other ingredients.
Unlike other mood support herbs, such as St. John’s wort, Venetron® does not affect the CYP3A pathway or P-glycoprotein, ensuring safe use. Venetron® has attained self-affirmed GRAS status.
Additionally, Venetron® is also available as water-soluble Venetron®-W, making this low-dose ingredient an attractive candidate for manufacturers looking to develop products in a wide variety of formats such as tablets, capsules, gels, gummies, chocolates and beverages.
To learn more about Venetron® click here
This ingredient is not intended to diagnose, treat, cure or prevent any disease.